Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study conducted a bibliometric analysis of non-muscle invasive bladder cancer research, finding increased publications over two decades, with leading contributions from the United States and European institutions.

In this case report, botulinum neurotoxin injections were associated with a 6-month cessation of priapism episodes in a young man with recurring low-flow priapism, following unsuccessful conventional treatments.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

Regenerative repair is essential to prevent long-term kidney function issues after obstruction.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study identified several patient-specific factors that can predict both the likelihood of undergoing and failing a post-TURP void trial, aiding in the selection of candidates for immediate assessment.

This article highlights the complexity of diagnosing hyponatremia in older adults, emphasizing the need to evaluate urinary tract obstruction, medication effects, and age-related changes rather than relying solely on spot urinary values.

This study found that men prescribed Finasteride had a lower incidence of bladder cancer compared to those not on the medication, but this protective effect was observed only in Caucasians and Hispanics.

This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This paper discusses the potential of targeting fibrosis in addressing lower urinary tract symptoms associated with benign prostatic hyperplasia, but it provides no new clinical findings and highlights the need for further research.

Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.

Platelet-rich plasma shows promise in reducing pain for bladder pain syndrome.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study found that depression, anxiety, and sleep disturbance were associated with male lower urinary tract symptoms, but these factors did not predict improvement after evaluation and treatment over time.

This editorial comment references research on finasteride's effects on urinary retention and surgical needs in benign prostatic hyperplasia but reports no new findings.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

Self-management can help improve symptoms of benign prostatic hyperplasia.

This case report discusses an instance of cystitis caused by the chemotherapy drug Cytoxan, with no new findings reported.

This study found that a substantial number of patients continued tamsulosin and/or finasteride unnecessarily after prostate surgery, with poor documentation and communication contributing to this issue.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This article reviews various topics in adult urology, including biopsy complications and urinary tract symptom management, but does not present new research findings.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

Finasteride and dutasteride can affect sexual function in BPH patients.